Get the Stockscreener App
0.00
100.00%
-5.34
Generation Bio Co stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.
See More
Previous Close:
$5.34
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$35.98M
Revenue:
$15.27M
Net Income/Loss:
$-62.63M
P/E Ratio:
0.00
EPS:
-7.3629
Net Cash Flow:
$-114.74M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$6.95
Generation Bio Co Stock (GBIO) Company Profile
Name
Generation Bio Co
Sector
Industry
Phone
857-529-5908
Address
301 BINNEY STREET, CAMBRIDGE
Compare GBIO vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GBIO
Generation Bio Co
|
0.00 | 35.98M | 15.27M | -62.63M | -114.74M | -7.3629 |
VRTX
Vertex Pharmaceuticals Inc
|
443.81 | 110.81B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
633.19 | 66.02B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
791.40 | 48.27B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
293.07 | 38.22B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
145.64 | 30.69B | 742.00K | -1.37B | -1.07B | -7.0731 |
Generation Bio Co Stock (GBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-25 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-25 | Upgrade | Wedbush | Neutral → Outperform |
| Aug-13-25 | Downgrade | Wedbush | Outperform → Neutral |
| Oct-19-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Nov-08-22 | Initiated | Canaccord Genuity | Buy |
| Dec-14-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-08-21 | Initiated | JMP Securities | Mkt Outperform |
| Feb-24-21 | Initiated | William Blair | Outperform |
| Feb-18-21 | Initiated | Needham | Buy |
| Jul-07-20 | Initiated | Cowen | Outperform |
| Jul-07-20 | Initiated | JP Morgan | Overweight |
| Jul-07-20 | Initiated | Jefferies | Buy |
| Jul-07-20 | Initiated | Wedbush | Outperform |
View All
Generation Bio Co Stock (GBIO) Latest News
Generation Bio stock (US37148B1061): Trial momentum keeps investors watching - AD HOC NEWS
Generation Bio stock: Trial momentum keeps investors watching - AD HOC NEWS
Organic wastes to next-generation bioplastics through intelligent biomanufacturing of polyhydroxyalkanoates - Nature
Cosmax China unveils next-generation bio beauty solutions at China Expo - theinvestor.co.kr
Atlas Venture amends 13G/A on GBIO holdings (GBIO) - Stock Titan
TradingKey - TradingKey
ParcelBio Launches with $13 Million in Financing to Advance Next-Generation mRNA Medicines - Business Wire
Samsung Bioepis announced on the 29th that it will sign a memorandum of understanding (MOU) with the.. - 매일경제
XOMA (XOMA) closes Generation Bio acquisition, details cash-plus-CVR terms and LNP assets - Stock Titan
Generation Bio Co. (GBIO) Reports Q1 Loss, Tops Revenue Estimates - MSN
Firm secures £100k to develop next generation plastics - The Argus
Low-energy path to bioplastics emerges from discarded wood - The Korea Times
Eli Lilly acquires Houston biotech startup for $300M - Houston Chronicle
CrossBridge Bio Enters an Agreement to be Acquired by Eli Lilly to Advance Next-Generation Dual-Payload Antibody-Drug Conjugates - Business Wire
National Growth Fund Invests in SK Bioscience… Supporting Next-Generation Bio and Vaccine Development - Seoul Economic Daily
Retail Trends: Why is Generation Bio Co stock going downQuarterly Profit Summary & Safe Entry Momentum Stock Tips - baoquankhu1.vn
GBIO SEC FilingsGeneration Bio Co. 10-K, 10-Q, 8-K Forms - Stock Titan
Fed Meeting: Will Generation Bio Co benefit from AI trends2026 Rallies & Expert-Curated Trade Recommendations - baoquankhu1.vn
Sell Signal: Will Generation Bio Co benefit from AI trends2026 Analyst Calls & Smart Investment Allocation Tips - baoquankhu1.vn
Generation Bio Co stock: Why this gene therapy innovator merits your watchlist now - AD HOC NEWS
XOMA SEC FilingsXOMA Royalty Corporation 10-K, 10-Q, 8-K Forms - Stock Titan
Investment Report: Whats the beta of Generation Bio Co stock2026 Geopolitical Influence & AI Driven Price Forecasts - baoquankhu1.vn
If You Invested $1,000 in Generation Bio Co. (GBIO) - Stock Titan
Wedbush Downgrades Generation Bio (GBIO) - MSN
Aug Spikes: Whats the beta of Generation Bio Co stockWeekly Loss Report & Safe Entry Point Identification - baoquankhu1.vn
Jefferies downgrades Generation Bio (GBIO) - MSN
Samsung Bioepis Enters into Partnership Agreement with Sandoz for Up to Five Next-Generation Biosimilar Candidates - Businesskorea
Will Generation Bio Co benefit from green energy policiesTrade Exit Report & Daily Profit Maximizing Trade Tips - baoquankhu1.vn
How interest rate cuts could boost Generation Bio Co. stockDividend Hike & AI Based Trade Execution Alerts - Naître et grandir
Performance Recap: Can Generation Bio Co grow without external fundingMarket Growth Report & Free Community Consensus Stock Picks - baoquankhu1.vn
Universidade de Aveiro - Universidade de Aveiro
Generation Bio (GBIO) to Release Earnings on Thursday - Defense World
Sironix Renewables Launches Furasoft™Next Generation, Bio-Based Surfactant for Personal Care - The Manila Times
Generation Bio Co. (NASDAQ:GBIO) Receives Average Recommendation of “Hold” from Brokerages - Defense World
GBIO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
MegazoneCloud to work with CellKey AI on global business for bio AI solutions - 디지털투데이
[15-12G] Generation Bio Co. SEC Filing - Stock Titan
T. Rowe Price holds 3.1% of Generation Bio (GBIO) shares - Stock Titan
Will Generation Bio Co. benefit from green energy policiesJuly 2025 Sector Moves & Daily Volume Surge Trade Alerts - mfd.ru
Generation Bio (NASDAQ:GBIO) Stock Rating Upgraded by Wall Street Zen - Defense World
Xoma stock rating reinstated as Hold by TD Cowen after Generation Bio acquisition - Investing.com Australia
Bear Alert: Why is Generation Bio Co. stock going downJuly 2025 Analyst Calls & Stock Portfolio Risk Management - mfd.ru
Why Generation Bio Co. stock remains undervaluedWeekly Gains Summary & Fast Moving Stock Watchlists - mfd.ru
Baselake exits Generation Bio (NASDAQ: GBIO) reporting 0% ownership stake - Stock Titan
New Highs: What drives Generation Bio Co.’s stock priceShort Setup & Weekly Sector Rotation Insights - mfd.ru
Generation Bio pays landlord $21.5M to escape lease early after Xoma buyout - The Business Journals
Biotech Firm Terminates Cambridge Headquarters Lease Early - connectcre.com
XOMA Royalty completes acquisition of Generation Bio for $4.29 per share By Investing.com - Investing.com South Africa
XOMA Royalty completes acquisition of Generation Bio for $4.29 per share - Investing.com Nigeria
XOMA Royalty completes acquisition of Generation Bio; GBIO delisted from Nasdaq - Investing.com
XOMA Completes Acquisition and Delisting of Generation Bio - TipRanks
Generation Bio Co Stock (GBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.93%
0.98%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):